Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021

Date: August 9, 2016
Pages: 159
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V1EF8A3C425EN
Leaflet:

Download PDF Leaflet

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021
The vaccines market is expected to reach USD 48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3%. The global vaccines market is segmented based on technology, type, disease indication, end-users, and regions. The conjugate vaccines segment is expected to register the highest growth rate in the vaccines market, by technology, during the forecast period. The high growth in this segment is attributed to the increasing company investments in development of new vaccines.

Based on end-users, the vaccines market is segmented into paediatrics and adults. The paediatrics segment is expected to account for the largest share of the market in 2016. Increasing prevalence of diseases in children and the rising number of awareness programs to promote vaccination will drive the growth of this market.

Geographically, the vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rising government funding for vaccine research in the North American countries.

The major factors contributing to the growth of the vaccines market include high prevalence of diseases, rising government and nongovernment funding for vaccine development, and increasing focus on immunization programs. Furthermore, increasing R&D spending and new vaccine development activities by companies is another major factor driving the growth of this market.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The major players in this market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyses the vaccines market by technology, type, disease indication, end-users, and regions
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccines market
  • Market Development: Comprehensive information about emerging markets. This report analyses the market for various vaccines across geographies
  • Market Diversification: Exhaustive information about new vaccines, untapped geographies, recent developments, and investments in the vaccines market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 MARKET SEGMENTATION
  1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATION
1.5 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.4 KEY DATA FROM SECONDARY SOURCES
2.5 KEY DATA FROM PRIMARY SOURCES
2.6 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION

4 PREMIUM INSIGHTS

4.1 GLOBAL VACCINES MARKET
4.2 VACCINES MARKET, BY TYPE
4.3 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY END USER
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY
4.5 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET
4.6 LIFECYCLE ANALYSIS, BY REGION, 2016

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
5.3 MARKET DYNAMICS
  5.3.1 DRIVERS
    5.3.1.1 High prevalence of diseases
    5.3.1.2 Rising government and non-government funding for vaccine development
    5.3.1.3 Increasing investments by companies
    5.3.1.4 Increasing government focus on immunization programs
  5.3.2 RESTRAINTS
    5.3.2.1 Huge capital investments
    5.3.2.2 Stringent regulations
  5.3.3 OPPORTUNITIES
    5.3.3.1 High growth prospects in emerging markets
    5.3.3.2 Therapeutic vaccines
    5.3.3.3 Adjuvant vaccines
  5.3.4 CHALLENGES
    5.3.4.1 Inadequate access to vaccines
    5.3.4.2 Vaccine pricing
  5.3.5 BURNING ISSUES
    5.3.5.1 Vaccine failure
5.4 INVESTMENT ANALYSIS
5.5 REGULATORY LANDSCAPE
  5.5.1 NORTH AMERICA
  5.5.2 EUROPE
  5.5.3 ASIA
  5.5.4 ROW
5.6 PATENT ANALYSIS
5.7 KEY PIPELINE PRODUCTS

6 VACCINES MARKET, BY TECHNOLOGY

6.1 INTRODUCTION
6.2 CONJUGATE VACCINES
6.3 INACTIVATED AND SUBUNIT VACCINES
6.4 LIVE ATTENUATED VACCINES
6.5 TOXOID VACCINES
6.6 RECOMBINANT VACCINES

7 VACCINES MARKET, BY TYPE

7.1 INTRODUCTION
7.2 MONOVALENT VACCINES
7.3 MULTIVALENT VACCINES

8 VACCINES MARKET, BY DISEASE INDICATION

8.1 INTRODUCTION
8.2 PNEUMOCOCCAL DISEASE
8.3 DTP
8.4 INFLUENZA
8.5 HUMAN PAPILLOMA VIRUS
8.6 MENINGOCOCCAL DISEASE
8.7 POLIO
8.8 ROTAVIRUS
8.9 HEPATITIS
8.10 MMR
8.11 VARICELLA
8.12 OTHERS

9 VACCINES MARKET, BY END USER

9.1 INTRODUCTION
9.2 PEDIATRICS
9.3 ADULTS

10 VACCINES MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 U.S.
  10.2.2 CANADA
10.3 EUROPE
  10.3.1 GERMANY
  10.3.2 U.K.
  10.3.3 FRANCE
  10.3.4 ITALY
  10.3.5 SPAIN
  10.3.6 REST OF EUROPE (ROE)
10.4 ASIA
  10.4.1 JAPAN
  10.4.2 CHINA
  10.4.3 INDIA
  10.4.4 REST OF ASIA (ROA)
10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SITUATION AND TRENDS
  11.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  11.3.2 REGULATORY APPROVALS
  11.3.3 ACQUISITIONS
  11.3.4 EXPANSIONS
  11.3.5 OTHER DEVELOPMENTS

12 COMPANY PROFILES

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

12.1 INTRODUCTION
12.2 PFIZER, INC.
12.3 GLAXOSMITHKLINE, PLC.
12.4 MERCK & CO., INC.
12.5 SANOFI PASTEUR
12.6 CSL LIMITED
12.7 EMERGENT BIOSOLUTIONS, INC.
12.8 JOHNSON & JOHNSON
12.9 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA)
12.10 ASTELLAS PHARMA INC.
12.11 SERUM INSTITUTE OF INDIA

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS

LIST OF FIGURES

Figure 1 VACCINES MARKET SEGMENTATION
Figure 2 RESEARCH DESIGN
Figure 3 TOP-DOWN APPROACH
Figure 4 BOTTOM-UP APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 VACCINES MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021 (USD MILLION)
Figure 8 GLOBAL VACCINES MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
Figure 9 GLOBAL VACCINES MARKET, BY DISEASE INDICATION, 2016
Figure 10 GLOBAL VACCINES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
Figure 11 GLOBAL VACCINES MARKET, BY REGION, 2016 (USD MILLION)
Figure 12 HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NON-GOVERNMENT FUNDING FOR VACCINE DEVELOPMENT—PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET
Figure 13 MONOVALENT VACCINES SEGMENT TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
Figure 14 PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN 2021
Figure 15 CONJUGATE VACCINES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
Figure 16 U.S. TO DOMINATE THE VACCINES MARKET IN 2016
Figure 17 ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET DURING THE FORECAST PERIOD
Figure 18 VACCINE MARKET SEGMENTATION
Figure 19 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 20 INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET
Figure 21 VACCINE FUNDING, BY INVESTOR, 2014
Figure 22 GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014
Figure 23 HIV PREVENTIVE VACCINES R&D FUNDING, BY INVESTOR, 2014
Figure 24 REGULATORY APPROVAL PROCESS FOR VACCINES
Figure 25 NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS IN 2012
Figure 26 THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012)
Figure 27 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD
Figure 28 ASIAN MARKET FOR LIVE ATTENUATED VACCINES TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 29 NORTH AMERICA IS EXPECTED TO DOMINATE THE RECOMBINANT VACCINES MARKET DURING THE FORECAST PERIOD
Figure 30 MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2016 TO 2021
Figure 31 NORTH AMERICA IS EXPECTED TO DOMINATE THE MULTIVALENT VACCINES MARKET DURING THE FORECAST PERIOD
Figure 32 PNEUMOCOCCAL DISEASE SEGMENT EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
Figure 33 ASIA IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE INFLUENZA DISEASE SEGMENT DURING THE FORECAST PERIOD
Figure 34 NORTH AMERICA TO DOMINATE THE MENINGOCOCCAL DISEASE MARKET DURING THE FORECAST PERIOD
Figure 35 ASIAN MARKET FOR HEPATITIS VACCINES TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 36 THE PEDIATRICS END-USER SEGMENT DOMINATES THE GLOBAL VACCINES MARKET IN 2016
Figure 37 ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET FOR ADULTS DURING THE FORECAST PERIOD
Figure 38 GEOGRAPHIC SNAPSHOT (2016): EMERGING MARKETS TO OFFER GROWTH OPPORTUNITIES
Figure 39 GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET
Figure 40 NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2016
Figure 41 EUROPE: VACCINES MARKET SNAPSHOT, 2016
Figure 42 ASIA: VACCINES MARKET SNAPSHOT, 2016
Figure 43 ORGANIC AND INORGANIC GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS FROM 2013 TO 2016
Figure 44 GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2015
Figure 45 BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WERE THE PREFERRED STRATEGIES BY MARKET PLAYERS
Figure 46 PRODUCT BENCHMARKING FOR TOP 4 MARKET PLAYERS
Figure 47 PFIZER, INC.: COMPANY SNAPSHOT
Figure 48 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT
Figure 49 MERCK & CO., INC.: COMPANY SNAPSHOT
Figure 50 SANOFI PASTEUR: COMPANY SNAPSHOT
Figure 51 CSL LIMITED: COMPANY SNAPSHOT
Figure 52 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
Figure 53 JOHNSON & JOHNSON: COMPANY SNAPSHOT
Figure 54 ASTRAZENECA: COMPANY SNAPSHOT
Figure 55 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%. The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others – Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR.

The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years. Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers.

North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

The key players in this market are Novartis (Switzerland), Glaxo Smithkline (U.K.), Merck (U.S.), Sanofi (France), Pfizer (U.S.), Antigen Express, Inc. (U.S.), Aduro Biotech (U.S.), Genticel (France), Biondvax (Israel), Immune Targeting Systems (U.K.), Prokarium (U.K.), Immunobiology Ltd. (U.K.), Liquidia Technologies (U.S.), Alphavax (U.S.), and Bavarian Nordic (Denmark).

The material was prepared in August, 2013.

LIST OF TABLES

Table 1 INCIDENCE OF DISEASES, 2014-2015
Table 2 NIH FUNDING FOR VACCINE RESEARCH, 2012-2016 (USD MILLION)
Table 3 HIGH PREVALENCE OF DISEASES TO BOOST THE VACCINES MARKET
Table 4 HUGE CAPITAL INVESTMENTS TO LIMIT THE MARKET GROWTH OF VACCINES
Table 5 HIGH GROWTH POTENTIAL IN EMERGING COUNTRIES TO BOOST THE MARKET FOR VACCINES
Table 6 IMMUNIZATION COVERAGE, BY DISEASE, 2014
Table 7 INADEQUATE ACCESS TO VACCINES A MAJOR CHALLENGE IN THE MARKET
Table 8 REGULATORY AUTHORITIES IN EUROPE
Table 9 REGULATORY AUTHORITIES IN ASIA
Table 10 KEY PIPELINE VACCINES
Table 11 VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 12 CONJUGATE VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 13 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES
Table 14 INACTIVATED AND SUBUNIT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 15 LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 16 TOXOID VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 17 RECOMBINANT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 18 VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 19 MONOVALENT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 20 EXAMPLES OF MULTIVALENT VACCINES
Table 21 MULTIVALENT VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 22 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION)
Table 23 LIST OF PNEUMOCOCCAL VACCINES
Table 24 VACCINES MARKET SIZE FOR PNEUMOCOCCAL DISEASE, BY REGION, 2014–2021 (USD MILLION)
Table 25 LIST OF DTP VACCINES
Table 26 VACCINES MARKET SIZE FOR DTP, BY REGION, 2014–2021 (USD MILLION)
Table 27 LIST OF INFLUENZA VACCINES
Table 28 VACCINES MARKET SIZE FOR INFLUENZA, BY REGION, 2014–2021 (USD MILLION)
Table 29 LIST OF HPV VACCINES
Table 30 VACCINES MARKET FOR HPV, BY REGION, 2014–2021 (USD MILLION)
Table 31 LIST OF MENINGOCOCCAL VACCINES
Table 32 VACCINES MARKET SIZE FOR MENINGOCOCCAL DISEASE, BY REGION, 2014–2021 (USD MILLION)
Table 33 LIST OF POLIO VACCINES
Table 34 POLIO MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 35 LIST OF ROTAVIRUS VACCINES
Table 36 VACCINES MARKET SIZE FOR ROTAVIRUS, BY REGION, 2014–2021 (USD MILLION)
Table 37 LIST OF HEPATITIS VACCINES
Table 38 VACCINES MARKET SIZE FOR HEPATITIS, BY REGION, 2014–2021 (USD MILLION)
Table 39 LIST OF MMR VACCINES
Table 40 VACCINES MARKET SIZE FOR MMR, BY REGION, 2014–2021 (USD MILLION)
Table 41 LIST OF VARICELLA VACCINES
Table 42 VACCINES MARKET SIZE FOR VARICELLA, BY REGION, 2014–2021 (USD MILLION)
Table 43 LIST OF OTHER VACCINES
Table 44 VACCINES MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014–2021 (USD MILLION)
Table 45 VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 46 VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2014–2021 (USD MILLION)
Table 47 NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 48 VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2014–2021 (USD MILLION)
Table 49 NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 50 VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 51 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 52 NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 53 NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 54 NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION)
Table 55 NORTH AMERICA: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 56 U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 57 U.S.: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 58 CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 59 CANADA: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 60 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 61 EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 62 EUROPE: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 63 EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION)
Table 64 EUROPE: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 65 GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 66 U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 67 FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 68 ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 69 SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 70 ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 71 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD)
Table 72 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 73 ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 74 ASIA: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 75 ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION)
Table 76 ASIA: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 77 JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 78 CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 79 INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 80 ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 81 ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION)
Table 82 ROW: VACCINES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 83 ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD MILLION)
Table 84 ROW: VACCINES MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 85 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013-2016
Table 86 REGULATORY APPROVALS, 2013-2016
Table 87 ACQUISITIONS, 2013-2016
Table 88 EXPANSIONS, 2013-2016
Table 89 OTHER DEVELOPMENTS, 2013-2016

Skip to top


Ask Your Question

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: